Immune homeostasis in tissues is achieved through a delicate balance between pathogenic T-cell responses directed at tissuespecific antigens and the ability of the tissue to inhibit these responses. The mechanisms by which tissues and the immune system communicate to establish and maintain immune homeostasis are currently unknown. Clinical evidence suggests that chronic or repeated exposure to self antigen within tissues leads to an attenuation of pathological autoimmune responses, possibly as a means to mitigate inflammatory damage and preserve function. Many human organ-specific autoimmune diseases are characterized by the initial presentation of the disease being the most severe, with subsequent flares being of lesser severity and duration 1 . In fact, these diseases often spontaneously resolve, despite persistent tissue autoantigen expression 2 . In the practice of antigenspecific immunotherapy, allergens or self antigens are repeatedly injected in the skin, with a diminution of the inflammatory response occurring after each successive exposure 3 . Although these findings indicate that tissues acquire the ability to attenuate autoimmune reactions upon repeated responses to antigens, the mechanism by which this occurs is unknown. Here we show that upon expression of self antigen in a peripheral tissue, thymusderived regulatory T cells (T reg cells) become activated, proliferate and differentiate into more potent suppressors, which mediate resolution of organ-specific autoimmunity in mice. After resolution of the inflammatory response, activated T reg cells are maintained in the target tissue and are primed to attenuate subsequent autoimmune reactions when antigen is re-expressed. Thus, T reg cells function to confer 'regulatory memory' to the target tissue. These findings provide a framework for understanding how T reg cells respond when exposed to self antigen in peripheral tissues and offer mechanistic insight into how tissues regulate autoimmunity.
We hypothesized that exposure of immune cells to self antigen in peripheral tissues induces stable regulatory mechanisms that limit autoimmune injury. To test this and to define the nature of these control mechanisms, we created a novel mouse model of inducible tissue-specific self-antigen expression. We crossed transgenic mice expressing a membrane-bound form of ovalbumin (Ova) under the control of a tetracycline response element to transgenic mice expressing the tetracycline transactivator protein under the control of the keratin 5 (K5, also called Krt5) promoter (Fig. 1a) 4 . In the resultant K5/ TGO double transgenic mice (see Methods for definition of TGO), Ova expression in the skin is tightly controlled, as adoptively transferred Ova-specific DO11.10 (DO11) CD4
1 T cells become activated and proliferate in skin-draining lymph nodes (SDLNs) of recipient mice only after treatment with doxycycline (Fig. 1b) . In addition, Ova messenger RNA is detected in epidermal cell suspensions only after induction with doxycycline ( Supplementary Fig. 1 ).
To define functional Ova expression in the thymus, K5/TGO mice were crossed with the DO11.10 T-cell receptor (TCR)-transgenic strain 5 . Deletion of CD4 1 DO11 T cells or increased production of Foxp3 1 CD4 1 DO11 T reg cells in K5/TGO/DO11 mice is a sensitive indicator of thymic Ova expression. K5/TGO/DO11 triple transgenic mice as well as TGO/DO11 double transgenic mice have modest deletion of CD4 1 DO11 cells (Fig. 1c) and a pronounced increase in DO11 T reg cells in both the thymus and SDLNs (Fig. 1c, d ). Between 30-40% of antigen-specific CD4
1 DO11 T cells in the SDLNs of K5/TGO/ DO11 (and TGO/DO11) mice co-express CD25 and Foxp3 (Fig. 1d ). These results demonstrate that Ova is constitutively expressed in the thymus, independent of doxycycline treatment and dependent only on the presence of the TGO transgene. Thus, K5/TGO/DO11 mice represent a unique model in which antigen is continuously expressed in the thymus and tightly controlled in the periphery, mimicking the pattern of tissue-specific self-antigen expression in mice and humans 6, 7 .
Despite the presence of a large percentage of Ova-specific T reg cells, induction of cutaneous Ova expression in K5/TGO/DO11 mice results in a pronounced inflammatory dermatitis (Fig. 2a) . Disease peaks at 10-14 days after antigen induction and is characterized by marked erythema, scaling and alopecia (Fig. 2b) . The skin infiltrate at the height of disease is composed primarily of antigen-specific DO11 T cells and GR-1 1
CD11b
1 myeloid cells (Fig. 2c) . Ova-specific skininfiltrating CD4
1 T cells produce interferon (IFN)-c and interleukin (IL)-17 ( Fig. 2j) .
Interestingly, skin inflammation spontaneously resolves. Twenty to 30 days after antigen induction, mice begin to show signs of clinical and histological improvement, and by 40 to 60 days, there is complete resolution of cutaneous inflammation (Fig. 2d-f) . Disease resolves despite continued doxycycline treatment, with ongoing Ova expression in the skin and continuous thymic output of Ova-specific T cells (Supplementary Fig. 2 ).
Given the large percentage of antigen-specific T reg cells present in the SDLNs of K5/TGO/DO11 mice, it is surprising that cutaneous inflammation results when antigen is induced. We were further intrigued by the spontaneous resolving nature of the autoimmune response, as it suggests that an immune regulatory mechanism(s) is initiated in an attempt to minimize tissue damage. To determine if T reg cells have a role in resolving skin inflammation, we depleted these cells before antigen induction and at the height of disease. Treatment of K5/ TGO/DO11 mice with CD25-depleting antibody (PC61) before antigen induction resulted in pronounced disease exacerbation with delayed resolution of skin inflammation (Fig. 2g, h) . In some experiments, depletion of T reg cells resulted in dehydration, weight loss and death, most likely from severely disrupted skin barrier function (Supplementary Fig. 3 ). Depletion of T reg cells at the height of disease (that is, 10 days after antigen induction) resulted in delayed kinetics of resolution of skin inflammation, with some mice having to be euthanized secondary to non-resolving skin disease (Fig. 2i ). Higher percentages of both IFN-cand IL-17-secreting DO11 cells were observed in the skin and SDLN after T reg cell depletion (Fig. 2j) . Anti-CD25 antibody was used in these studies because CD25 is constitutively expressed on T reg cells and antibody treatment can be accurately titrated to achieve optimal deletion of these cells ( Supplementary Fig. 4 ). A caveat of this approach is that other CD25-expressing cells (which may be either tolerance-promoting or pathogenic) might also be deleted. The finding that anti-CD25 antibody treatment inhibits or prevents disease resolution strongly suggests that T reg cells are the major targets of the antibody and have an essential role in resolving skin disease in our model; however, depletion of other CD25-expressing regulatory populations cannot be definitively ruled out.
The emergence of disease despite the presence of T reg cells and the T reg cell-dependent suppression of disease after antigen induction suggested that expression of tissue antigen activates T reg cells and enhances their suppressive function. To test this, we induced Ova expression in K5/TGO/DO11 mice and characterized T reg cells in both the skin and SDLNs. Foxp3 1 DO11 cells robustly expanded in SDLNs upon antigen induction (Fig. 3a) . Expansion peaked at 12-14 days, when these cells were increased ,15-fold over baseline numbers. In contrast, the peak expansion of Foxp3 2 DO11 effector cells occurred earlier and these cells only expanded ,4-fold over baseline (Fig. 3a) . At the peak of expansion, more than 50% of Foxp3 1 DO11 cells had markedly reduced CD25 on the cell surface ( 
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has been reported by others 8 . It is possible that proliferating T reg cells reduce expression of CD25 in a negative feedback loop to limit proliferation and regulate T reg cell numbers. SDLN T reg cells in the resolution phase of disease have increased expression of Foxp3 and CD25 when compared to T reg cells from non-induced mice ( Fig. 3b and Supplementary Fig. 5 ). These results indicate that T reg cells are activated upon exposure to peripheral antigen. To test this further, we analysed expression levels of various markers shown to be involved in T reg cell function early after antigen induction. Six days after inducing Ova expression in the skin, .80% of T reg cells have entered the cell cycle, as shown by Ki67 expression, and proliferating CD25 1 and CD25
2 T reg cells express higher levels of CTLA-4 compared to T reg cells from non-induced mice (Fig. 3c) .
Expansion of T reg cells in SDLNs upon antigen induction is associated with an accumulation of these cells in the skin (Fig. 3d) . Before antigen induction, CD4
1 DO11 cells are barely detectable in the skin. At the height of disease, most skin-infiltrating DO11 cells are Foxp3
However, resolution of inflammation is associated with a preferential accumulation of Foxp3 1 cells in the skin, with .60% of DO11 cells in the skin expressing Foxp3 in mice maintained on doxycycline that have resolved disease (that is, clinically and histologically normal appearing skin) (Fig. 3d) .
We next tested whether T reg cells acquire a more suppressive phenotype after exposure to tissue antigen. To do so, we crossed K5/TGO/ DO11 mice with Foxp3 GFP reporter mice 9 . K5/TGO/DO11/Foxp3 GFP mice were treated with doxycycline to induce antigen expression in the skin, and 6 days later, CD4 2 T reg cells from antigen-induced mice were more potent suppressors of effector T-cell proliferation in vitro when compared to T reg cells isolated from noninduced mice (that is, peripheral antigen naive) at all effector to suppressor ratios examined (Fig. 3e) . In addition, T reg cells from antigen-induced mice were more potent suppressors of cutaneous autoimmune responses in vivo. Upon co-transfer with naive DO11 responder cells into K5/TGO double transgenic mice (and treatment of recipient mice with doxycycline to induce Ova expression in the skin), both CD25
1 and CD25 2 Foxp3 1 T reg cells isolated from antigen-induced K5/TGO/DO11/Foxp3 GFP mice were more potent at inhibiting T-cell proliferation when compared to Foxp3 1 cells isolated from non-induced mice (Fig. 3f) . These cells were also more potent inhibitors of IL-17 and IFN-c production from effector T cells (Fig. 3g) .
The mechanism of enhanced T reg cell suppression after peripheral antigen induction may involve CTLA-4, which is expressed at markedly higher levels after activation of T reg cells (Fig. 3c) and has been shown to be a critical mediator of T reg function in suppressing tissue inflammation 10 . In addition, CD25
1 and CD25 2 T reg cells had similarly high RESEARCH LETTER levels of CTLA-4 expression and are equally suppressive in vitro and in vivo. We were unable to detect cytokine production (including IL-10, IL-17 and IFN-c) from T reg cells before or after antigen induction, suggesting that a cytokine-mediated mechanism of suppression is unlikely (Fig. 2j and data not shown) .
Our results indicate that early after exposure to tissue autoantigen, T reg cells are activated, proliferate, differentiate into more potent suppressors, and progressively accumulate in the target tissue. These results are consistent with recent findings that two major populations of Foxp3
1 T reg cells exist in human peripheral blood, which have been called resting T reg cells and activated T reg cells 11 . Resting T reg cells are recently derived from the thymus, express low levels of CTLA-4, are not actively cycling, and are inferior suppressors when compared to activated T reg cells. In contrast, activated T reg cells are constitutively cycling, express higher levels of Foxp3 and CTLA-4, and are more potent suppressors. Longitudinal studies showed ongoing conversion of resting T reg cells to activated T reg cells in a healthy human volunteer, with T-cell-receptor clonotypes initially detected in the resting T reg cell subset found 18 months later in the activated T reg cell subset. These results suggest that in normal healthy individuals, resting T reg cells are continuously activated and proliferate into more potent activated T reg cells. Taken together with results presented here, we speculate that exposure to tissue self antigen may drive this process as a mechanism to inhibit and/or suppress autoimmunity.
We hypothesized that once T reg cells have been activated and accumulate in the skin, these cells are relatively stable and persist in the tissue. They would then be capable of suppressing subsequent autoimmune reactions when antigen is re-expressed. To test this, we induced antigen expression in K5/TGO/DO11 mice and upon resolution of skin disease, removed doxycycline for .30 days to effectively 'turn antigen off' in the skin. We then re-induced antigen expression and followed mice clinically. To confirm the absence of antigen expression upon cessation of doxycycline, we assessed activation and proliferation of adoptively transferred DO11 cells and activation of endogenous DO11 cells in K5/TGO/DO11 mice (as a surrogate marker of antigen expression) at various times after discontinuing doxycycline. In addition, we measured Ova mRNA levels in the skin. At 20 days after discontinuing doxycycline treatment there was no proliferation of adoptively transferred DO11 cells and by 29 days, CD44 and CD69 expression had returned to baseline levels on adoptively transferred and endogenous DO11 cells, respectively (Fig. 4a and Supplementary Fig. 6a) . Expression of Ova mRNA was undetectable in all mice at 32 days after stopping doxycycline treatment (Supplementary Fig. 6b ). Taken together, these data confirm that antigen expression is effectively 'turned off' in all mice by 30 days after cessation of doxycycline treatment. Analysis of DO11 T cells in the skin of K5/ TGO/DO11 mice that had been off doxycycline for .30 days revealed a persistent Foxp3 1 population comprising .50% of DO11 cells in the skin (Fig. 4b) . The proportion of DO11 cells in the skin that were Foxp3 1 was enriched relative to SDLNs, indicating a preferential accumulation of T reg cells in the target tissue upon cessation of antigen expression (Fig. 4b) . Furthermore, T reg cells in the skin continued to express high levels of CTLA-4 (Fig. 4c) . When compared to T reg cells in the SDLN, cells that persisted in the skin (in the absence of antigen expression) expressed lower levels of CD25 and higher levels of CTLA-4, CD127 and KLRG1 (Fig. 4d) . The persistence of activated T reg cells in the skin indicated that there may be an attenuation of cutaneous inflammation upon antigen re-expression, as T reg cells must be present in the skin to suppress autoimmunity 12 . To test this, we re-started doxycycline treatment and followed mice clinically. Upon antigen re-expression, K5/TGO/DO11 mice developed skin disease phenotypically similar to the disease that developed upon initial antigen expression; however, the severity of skin disease was significantly reduced and it resolved with accelerated kinetics (Fig. 4e) . Attenuated disease upon antigen re-exposure was not secondary to reduced numbers of DO11 cells, as these cells returned to baseline levels relatively early after cessation of doxycycline treatment (Supplementary Fig. 7 ). In addition, antigen-experienced DO11 T cells from K5/TGO/DO11 mice that had resolved disease and were either maintained on doxycycline or were taken off doxycycline after resolution readily induced skin disease when adoptively transferred into new antigen-expressing hosts (Supplementary Fig. 8 ). This suggests that cell-intrinsic anergy in responding T cells does not seem to have a major role in attenuating skin inflammation. To test whether reduced disease severity upon second antigen exposure was mediated by T reg cells, we depleted these cells before re-inducing antigen expression. Depletion of T reg cells resulted in a complete abrogation of the attenuated response observed upon re-expression of Ova in the skin (Fig. 4f) .
Our results indicate that exposure to tissue autoantigens leads to the activation of self-reactive T reg cells that were generated by self-antigen expression in the thymus. Activated T reg cells persist in the target tissue and suppress autoimmune responses upon repeated or chronic encounters with tissue autoantigen. Thus, tissues that have undergone autoimmune inflammatory reactions develop a property we have termed regulatory memory, which serves to limit the severity of future such reactions. Memory T reg cells have several characteristics of effector memory cells 13, 14 , including survival without antigen, residence in non-lymphoid tissues, phenotypic markers suggestive of prior activation, and enhanced functional activity. The life history of 
Foxp3
1 DO11 cells from skin (shaded) and SDLN (unshaded) from K5/ TGO/DO11 mice that were on doxycycline for .30 days and off for .40 days. e, Clinical skin disease upon re-starting doxycycline in K5/TGO/DO11 mice that had been on doxycycline for .30 days and off for .30 days. f, Clinical skin disease of K5/TGO/DO11 mice treated with either PC61 or isotype control antibody before re-starting doxycycline. In all mice, antigen was induced, skin disease developed, and disease had resolved before antibody treatment. All error bars represent standard error of samples within each group. Mean clinical scores from individual mice are shown. Results are representative of 3 replicate experiments with 3-4 mice per group except for f, which is combined data from 2 replicate experiments with 2-4 mice per group. *P , 0.05 (t-test).
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T reg cells is fundamentally similar to that of conventional T cells, passing through defined phases that include generation in the thymus, activation in the periphery leading to proliferation and differentiation into functionally more active cells, and survival as memory populations. Although our data support an obligatory role for T reg cells in suppressing primary and memory responses in the skin, it is possible that these cells work together with other T reg -cell-independent mechanisms to suppress tissue-specific autoimmunity. Identifying and harnessing the network of regulatory pathways that serve to limit tissue inflammation will undoubtedly offer new strategies for controlling autoimmune reactions and preserving end-organ function.
METHODS SUMMARY
Mouse model. TRE-TGO mice were crossed with K5-rtTA mice to generate mice with inducible epidermal expression of Ova. The TGO construct encodes a fusion protein linking the transferrin receptor transmembrane domain, green fluorescent protein (GFP) and amino acids 230-359 of chicken ovalbumin. To create K5/ TGO/DO11 mice, K5-rTA/TRE-TGO mice were crossed onto the DO11.10 TCRtransgenic background. In all experiments, mice were gender-matched and between 5 and 24 weeks of age. All mice were bred and maintained in a specific pathogen-free facility in accordance with the guidelines of the Laboratory Animal Resource Center of the University of California San Francisco. Inflammatory skin disease model. To induce expression of the TGO transgene, K5/TGO/DO11 mice were maintained on 1 g kg 21 doxycycline chow. A 12-point clinical scoring scale was used to quantify skin disease. Scaling, alopecia, erythema and level of activity were each given a score from 0 to 3. Individual scores were summed and mean scores per group are displayed. T reg cell depletion. PC61 (anti-CD25 monoclonal antibody) or isotype control were injected intraperitoneally at 10 and 3 days before doxycycline treatment. For depletion at the height of disease, PC61 monoclonal antibody was injected on days 10 and 11 after starting K5/TGO/DO11 mice on doxycycline. For experiments in which CD25
1 cells were deleted before antigen re-expression, K5/TGO/DO11 mice that had been off doxycycline for .30 days were treated with PC61 at 7 and 3 days before restarting doxycycline. In vitro and in vivo suppression assays. K5/TGO/DO11 mice were crossed to Foxp3-GFP transgenic mice. K5/TGO/DO11/Foxp3-GFP mice were started on doxycycline and 6 days later, T reg cells were isolated. For in vitro suppression assays, T reg cells were cultured with CFSE-labelled SDLN cells isolated from DO11.10 
